However, the extensive redundancy of RTK-transducing pathways, cross-reactivity, toxicity and tumor resistance remain major challenges and limitations of targeting key protein kinases for cancer treatment (Fabbro et al., 2015). The gene discussed is WEE1; the disease is neoplasm.